Ipsen Aktie

155,10 EUR +0,60 EUR +0,39 %

16:50:59

STU

144,05 CHF +2,16 CHF +1,52 %

16:53:57

BRX

Ipsen jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)

Jetzt loslegen

Direkt handeln

Marktkap.13,15 Mrd. EUR

KGV22,18Div. Rendite1,34%

WKNA0ESMG

ISINFR0010259150

SymbolIPSEF

Ipsen Aktien News

Sortieren:Datum Meistgelesen

25.07.24GlobeNewswireIpsen S.A. publishes its 2024 Half-Year Report (half-year ended 30 June 2024)

25.07.24GlobeNewswireIpsen delivers strong results in the first half of 2024, progresses on launches and upgrades its full-year guidance

25.07.24GlobeNewswireIpsen and Day One enter into exclusive ex-U.S. licensing agreement to commercialize tovorafenib for the most common childhood brain tumor

23.07.24GlobeNewswireIPSEN - Buy-back programme - Art 5 of MAR - Week 29 - 2024

16.07.24GlobeNewswireIPSEN - Buy-back programme - Art 5 of MAR - Week 28 - 2024

11.07.24GlobeNewswireIpsen and Foreseen Biotechnology announce exclusive global licensing agreement for antibody-drug conjugate with first-in-class potential

09.07.24GlobeNewswireIpsen - June 2024 - Monthly information relative to the total number of voting rights and shares composing the share capital

09.07.24GlobeNewswireIPSEN - Buy-back programme - Art 5 of MAR - Week 27 - 2024

08.07.24GlobeNewswireHalf-year statement of IPSEN liquidity agreement - 2024 06 30

02.07.24GlobeNewswireIPSEN - Buy-back programme - Art 5 of MAR - Week 26 - 2024

02.07.24GlobeNewswireIpsen expands collaboration and license agreement for development of Cabometyx® in advanced neuroendocrine tumors based on positive CABINET Phase III trial

25.06.24GlobeNewswireIPSEN - Buy-back programme - Art 5 of MAR - Week 25 - 2024

18.06.24GlobeNewswireIPSEN - Buy-back programme - Art 5 of MAR - Week 24 - 2024

11.06.24GlobeNewswireIPSEN - Buy-back programme - Art 5 of MAR - Week 23 - 2024

10.06.24GlobeNewswireIpsen’s Iqirvo® receives U.S. FDA accelerated approval as a first-in-class PPAR treatment for primary biliary cholangitis

07.06.24GlobeNewswireIpsen and Marengo Therapeutics announce second strategic partnership to advance precision T cell engagers from Marengo’s Tri-STAR platform

06.06.24GlobeNewswireIpsen - Monthly information relative to the total number of voting rights and shares composing the share capital

06.06.24GlobeNewswireIpsen appoints Josep Catllà as EVP, Chief Corporate Affairs Officer

05.06.24GlobeNewswireIpsen presents long-term elafibranor efficacy and itch-related quality of life data in patients with primary biliary cholangitis

03.06.24GlobeNewswireIpsen initiates a share buy-back program to cover its free employee share-allocation plan

30.05.24GlobeNewswireIpsen announces the launch of an employee shareholding plan

28.05.24GlobeNewswireAnnual General Meeting of Ipsen S.A. held on 28 May 2024

28.05.24GlobeNewswireDescription of the regulatory framework of the share repurchase program proposed by the Board of Directors to be approved at Ipsen S.A.’s Annual General Meeting on 28 May 2024

07.05.24GlobeNewswireIpsen S.A. - Formalities for making available and consulting preparatory documents to the 2024 Annual General Meeting

06.05.24GlobeNewswireIpsen - Monthly information relative to the total number of voting rights and shares composing the share capital

02.05.24GlobeNewswireIpsen appoints Keira Driansky as EVP, President of North America

24.04.24GlobeNewswireIpsen delivers strong sales in the first quarter of 2024, driven by growth platforms & new medicines, and confirms its full-year guidance

24.04.24PR NewswireIpsen und Skyhawk Therapeutics geben Zusammenarbeit bei der Erforschung seltener neurologischer Erkrankungen durch RNA-Targeting bekannt

22.04.24PR NewswireIpsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases

22.04.24GlobeNewswireIpsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases

17.04.24GlobeNewswireIpsen publishes its 2023 Universal Registration Document

08.04.24GlobeNewswireIpsen - Monthly information relative to the total number of voting rights and shares composing the share capital

02.04.24PR NewswireMarengo Therapeutics Announces First Drug Candidate Nomination from Oncology Collaboration with Ipsen

02.04.24GlobeNewswireIpsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors

07.03.24GlobeNewswireIpsen - Monthly information relative to the total number of voting rights and shares composing the share capital

15.02.24GlobeNewswireIpsen S.A. publishes its 2023 Consolidated Financial Statements

13.02.24GlobeNewswireIpsen’s Onivyde® regimen, a potential new standard-of-care first-line therapy in metastatic pancreatic adenocarcinoma, approved by FDA

08.02.24GlobeNewswireBuilding on solid FY 2023 results, Ipsen anticipates four launches in 2024

Ipsen News

Ipsen News: auf dieser Seite finden Sie alle Ipsen News und Nachrichten zur Ipsen Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Ipsen News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Ipsen News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.